|
A Study To Test An Anti-Rejection Therapy After Kidney Transplantation Clinical Trials Data presented on Clinical Trials Search is not meant to be a substitute for qualified health advice, visits or treatment with a real mD. We are not doctors. Always consult your doctor about A Study To Test An Anti-Rejection Therapy After Kidney Transplantation conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. A Study To Test An Anti-Rejection Therapy After Kidney Transplantation Clinical research trials and A Study To Test An Anti-Rejection Therapy After Kidney Transplantation healthcare trials happen in many of places across the United States. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally assess the effectivity of new drugs. The purpose of the studies / projects is to solve particular human medical questions. Clinical trials are a popular way for doctors, government agencies, and private sector companies to discover cures for all varieties of conditions, such as A Study To Test An Anti-Rejection Therapy After Kidney Transplantation. A Study To Test An Anti-Rejection Therapy After Kidney Transplantation Clinical Trials and other clinical trials allow volunteers to have health treatment alternatives before they are available to the masses. Some times the human subjects obtain treatment for without cost, and sometimes they are compensated for their time. Occasionally there is a cost for a A Study To Test An Anti-Rejection Therapy After Kidney Transplantation clinical trial. Test subjects oftentimes receive the most effective healthcare possible for their A Study To Test An Anti-Rejection Therapy After Kidney Transplantation condition. Dangers are a reality, however, and may include extra or frequent physician visits, healthcare dangers (possibly life-jeopardising), and/or the treatment being uneffective. Trials are federally governed with rigorous guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "A" Clinical Trials Conditions > A Study To Test An Anti-Rejection Therapy After Kidney Transplantation  A Study To Test An Anti-Rejection Therapy After Kidney Transplantation
A Study To Test An Anti-Rejection Therapy After Kidney Transplantation
For Condition: Kidney Transplantation
Status: No longer recruiting
Sponsor(s): National Institute of Allergy and Infectious Diseases (NIAID) ,
Synopsis: Kidney transplantation is often successful. However, despite aggressive anti-rejection drug therapy, some patients will reject their new kidney. This study is designed to test two anti-rejection approaches. Two medications in this study are currently used in children, but there is no information regarding which drug is safer or more effective. Survival rates in renal transplantation are unacceptably low. Therefore, there is a need for an improved post-transplant treatment, such as the induction therapy used in this study.
Details: Renal transplantation is recognized as the treatment of choice for children with chronic renal failure. However, patient and graft survival rates in young children are unacceptably low. In preliminary studies, OKT3 (a monoclonal antibody) induction therapy received post transplant has been more successful than standard immunosuppression alone in improving graft survival. This study is designed to assess the impact of induction therapy on graft survival in pediatric kidney transplant patients. Patients are assigned to OKT3 induction or no induction in a 1:1 ratio. Randomization to oral cyclosporine of either Sandimmune or Neoral is also done in a 1:1 ratio. Group 1 receives OKT3 intraoperatively followed by Neoral. Group 2 receives OKT3 intraoperatively followed by Sandimmune. OKT3 is administered at 2.5 mg (if weight less than 30 kg) or 5 mg (if weight above 30 kg) per day for a maximum of 14 days. Group 3 receives IV cyclosporine followed by Neoral. Group 4 receives IV cyclosporine followed by Sandimmune. Oral cyclosporine is administered in a masked preparation. The dose for Sandimmune and Neoral is the same; patients 6 years of age and older begin at a dose of 15 mg/kg/day and patients under 6 years of age receive 500 mg/m2/day. Patients will receive concomitant medications including steroids (IV and po), Nifedipine, anti-CMV therapy, Bactrim, Azathioprine or Mycophenolate Mofetil. Kidney function, incidence of viral infection, graft survival, and incidence of malignancy will be measured to assess the role of OKT3 induction and the role of rejection in graft failure. Graft function will be evaluated at 1-, 2-, and 4-year intervals.
Eligibility:
Study Type: Interventional, Treatment
Minimum Age/Maximum Age: /20 Years
Genders: Both
Protocol Entry Criteria: Inclusion Criteria Children and young adults may be eligible for this study if they: - Are not yet 21 years of age. - Are receiving their first or second transplant. - Are not pregnant. - Agree to practice sexual abstinence or agree to use an effective - method of birth control/contraception during the study and - for 1 year after. Exclusion Criteria Children and young adults will not be eligible for this study if they: - Are recipients of multiple organs other than kidneys. - Are recipients of three or more transplants. - Are HIV positive. - Are Hepatitis B surface antigen positive.
Total Enrollment: 500
Location and Contact Information:
Ilene Blechman-Krom
Rockville, Maryland, 20850
United States
Additional Information:
Study ID Numbers: DAIT IN01/OLN-359;
Study Start Date:
Record last reviewed: September 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00000936
Other Kidney Transplantation Studies:
1. A Study of the Safety and Effectiveness of Varivax (the Chicken Pox Vaccine) in Children Who Have Received Kidney Transplants
2. Reducing the Risk of Transplant Rejection: Simultaneous Kidney and Bone Marrow Transplant
3. Pharmacokinetics of tacrolimus in kidney transplant recipients: Once daily versus twice daily dosing
4. Kidney and Liver Transplantation in People with HIV
5. Combination Therapy to Prevent Kidney Transplant Rejection
Related Studies:
Other Kidney Transplantation Clinical Trials
Other Maryland Clinical Trials
Other Rockville Clinical Trials
A Study To Test An Anti-Rejection Therapy After Kidney Transplantation
|
|
|
|
|
|
|
|
